

References

I-181

1. Talpur R, Thompson A, Gangar P, Duvic M. Pralatrexate alone or in combination with bexarotene: Long-term tolerability in relapsed/refractory mycosis fungoides. *Clinical Lymphoma, Myeloma & Leukemia*. 2014;297-304.
2. Petullo B, Wei L, Yereb M, et al. A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. *J Gastrointest Oncol*. 2015;336-340.
3. Ho AL, Lipson BL, Sherman EJ, et al. A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer. *Invest New Drugs*. (2014) 32:549–554.
4. MICROMEDEX®SOLUTIONS Compendia. 2017. Pralatrexate.
5. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Pralatrexate.
6. National Comprehensive Cancer Network (NCCN). Pralatrexate. NCCN Drugs and Biologics Compendium®. 2019.
7. Folutyn (pralatrexate), for injection [package insert]. Allos Therapeutics, Inc.. Westminster, CO. Revised 09/2019.
8. Advani RH, Ansell SM, Lechowicz MJ, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T- cell consortium trial. *British Journal of Haematology*. 2016;172(4):535-544.
9. Duvic M, Kim YH, Zinzani PL, et al. Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma. *Clin Cancer Res*. 2017;23(14):3552-3556.